These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 22139739)

  • 1. A hierarchical rank test for crossover trials with censored data.
    Brittain E; Follmann D
    Stat Med; 2011 Dec; 30(30):3507-19. PubMed ID: 22139739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incorporating baseline measurements into the analysis of crossover trials with time-to-event endpoints.
    Xu R; Mehrotra DV; Shaw PA
    Stat Med; 2018 Oct; 37(23):3280-3292. PubMed ID: 29888552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Assessing temporal agreement between central and local progression-free survival times.
    Zeng D; Cornea E; Dong J; Pan J; Ibrahim JG
    Stat Med; 2015 Feb; 34(5):844-58. PubMed ID: 25393731
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A review of statistical issues with progression-free survival as an interval-censored time-to-event endpoint.
    Sun X; Li X; Chen C; Song Y
    J Biopharm Stat; 2013; 23(5):986-1003. PubMed ID: 23957511
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A logrank test-based method for sizing clinical trials with two co-primary time-to-event endpoints.
    Sugimoto T; Sozu T; Hamasaki T; Evans SR
    Biostatistics; 2013 Jul; 14(3):409-21. PubMed ID: 23307913
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Weighted win loss approach for analyzing prioritized outcomes.
    Luo X; Qiu J; Bai S; Tian H
    Stat Med; 2017 Jul; 36(15):2452-2465. PubMed ID: 28343373
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Testing for qualitative heterogeneity: An application to composite endpoints in survival analysis.
    Oulhaj A; El Ghouch A; Holman RR
    Stat Methods Med Res; 2019 Jan; 28(1):151-169. PubMed ID: 28670972
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empirical power comparison of statistical tests in contemporary phase III randomized controlled trials with time-to-event outcomes in oncology.
    Horiguchi M; Hassett MJ; Uno H
    Clin Trials; 2020 Dec; 17(6):597-606. PubMed ID: 32933339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strengthening the interpretability of clinical trial results by assessing the effect of informative censoring on the primary estimand in PRECISION.
    Bao W; Gaffney M; Pressler ML; Fayyad R; Wisemandle W; Beckerman B; Wolski KE; Nissen SE
    Clin Trials; 2020 Oct; 17(5):535-544. PubMed ID: 32643966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluating and adjusting for premature censoring of progression-free survival.
    Rothmann M; Koti K; Lee KY; Lu HL; Shen YL; Zhang JJ; Jin M; Zhou H
    J Biopharm Stat; 2013; 23(5):1091-105. PubMed ID: 23957518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interaction trees with censored survival data.
    Su X; Zhou T; Yan X; Fan J; Yang S
    Int J Biostat; 2008 Jan; 4(1):Article 2. PubMed ID: 20231911
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Performance of Cox regression models for composite time-to-event endpoints with component-wise censoring in randomized trials.
    Speiser JL; Ambrosius WT; Pajewski NM
    Clin Trials; 2023 Oct; 20(5):507-516. PubMed ID: 37243355
    [TBL] [Abstract][Full Text] [Related]  

  • 13. On an enhanced rank-preserving structural failure time model to handle treatment switch, crossover, and dropout.
    Li L; Tang S; Jiang L
    Stat Med; 2017 May; 36(10):1532-1547. PubMed ID: 28110508
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A group sequential Holm procedure with multiple primary endpoints.
    Ye Y; Li A; Liu L; Yao B
    Stat Med; 2013 Mar; 32(7):1112-24. PubMed ID: 23239078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The win ratio: Impact of censoring and follow-up time and use with nonproportional hazards.
    Dong G; Huang B; Chang YW; Seifu Y; Song J; Hoaglin DC
    Pharm Stat; 2020 May; 19(3):168-177. PubMed ID: 31671481
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Practical application of cure mixture model for long-term censored survivor data from a withdrawal clinical trial of patients with major depressive disorder.
    Arano I; Sugimoto T; Hamasaki T; Ohno Y
    BMC Med Res Methodol; 2010 Apr; 10():33. PubMed ID: 20412598
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Nonignorable censoring in randomized clinical trials.
    Zhang J; Heitjan DF
    Clin Trials; 2005; 2(6):488-96. PubMed ID: 16422309
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Estimating the distribution of nonterminal event time in the presence of mortality or informative dropout.
    Jiang H; Chappell R; Fine JP
    Control Clin Trials; 2003 Apr; 24(2):135-46. PubMed ID: 12689735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Sample size in cluster-randomized trials with time to event as the primary endpoint.
    Jahn-Eimermacher A; Ingel K; Schneider A
    Stat Med; 2013 Feb; 32(5):739-51. PubMed ID: 22865817
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Statistical considerations when using a composite endpoint for comparing treatment groups.
    Gómez G; Lagakos SW
    Stat Med; 2013 Feb; 32(5):719-38. PubMed ID: 22855368
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.